We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: breast cancer
MedXY News
EnglishTag

breast cancer

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Vepdegestrant: A Next-Generation Oral PROTAC ER Degrader for Advanced ER+/HER2– Breast Cancer—VERITAC-2 Results and Clinical Implications
Clinical Updatesbreast cancerendocrine resistance

Vepdegestrant: A Next-Generation Oral PROTAC ER Degrader for Advanced ER+/HER2– Breast Cancer—VERITAC-2 Results and Clinical Implications

By MedXY|Oct 1, 2025

Vepdegestrant, an oral PROTAC estrogen receptor degrader, significantly prolongs progression-free survival compared to fulvestrant in ESR1-mutant advanced breast cancer, but not in the overall ER+/HER2– population.

No Added Survival Benefit from Adjuvant Chemotherapy in Older Women with Genomically High-Risk Hormone Receptor-Positive Breast Cancer: Results from the ASTER 70s Trial
Clinical Updates
adjuvant chemotherapy
breast cancer

No Added Survival Benefit from Adjuvant Chemotherapy in Older Women with Genomically High-Risk Hormone Receptor-Positive Breast Cancer: Results from the ASTER 70s Trial

By MedXY|Oct 1, 2025

The ASTER 70s trial found that adding chemotherapy to hormonotherapy did not improve survival but increased toxicity in women aged 70+ with high-risk ER+/HER2- breast cancer.

Tibremciclib Sets New Benchmark in Advanced HR+/HER2- Breast Cancer: Near Tripling of Progression-Free Survival
Clinical Updatesbreast cancerCDK4/6 inhibitor

Tibremciclib Sets New Benchmark in Advanced HR+/HER2- Breast Cancer: Near Tripling of Progression-Free Survival

By MedXY|Oct 1, 2025

The TIFFANY phase 3 trial demonstrates tibremciclib plus fulvestrant extends progression-free survival nearly threefold in advanced HR+/HER2- breast cancer following endocrine therapy, with a 63% risk reduction for progression or death and

One Exercise Session Can Fight Cancer! Latest Study Confirms: These Two Exercise Types Instantly Produce Anti-Cancer Substances That Significantly Inhibit Cancer Cell Growth
Family Medicine & Nutritionbreast cancerexercise

One Exercise Session Can Fight Cancer! Latest Study Confirms: These Two Exercise Types Instantly Produce Anti-Cancer Substances That Significantly Inhibit Cancer Cell Growth

By MedXY|Oct 1, 2025

A single session of resistance or high-intensity interval training boosts anti-cancer myokines in breast cancer survivors, significantly suppressing cancer cell growth in vitro.

Efficacy and Safety of 5 mg Olanzapine Added to Standard Antiemetics for Breast Cancer Chemotherapy: Insights from a Phase 3 Double-Blind Trial
Clinical Updatesbreast cancer

Efficacy and Safety of 5 mg Olanzapine Added to Standard Antiemetics for Breast Cancer Chemotherapy: Insights from a Phase 3 Double-Blind Trial

By MedXY|Oct 1, 2025

Adding 5 mg olanzapine after anthracycline-based chemotherapy significantly improves nausea and vomiting control with minimal sedation in breast cancer patients compared to standard antiemetic therapy alone.

Regional Nodal Irradiation After Neoadjuvant Chemotherapy: Is Omission Safe for Breast Cancer Patients with ypN0 Status?
Clinical Updatesbreast cancerclinical trial

Regional Nodal Irradiation After Neoadjuvant Chemotherapy: Is Omission Safe for Breast Cancer Patients with ypN0 Status?

By MedXY|Sep 30, 2025

A landmark trial shows that omitting regional nodal irradiation after neoadjuvant chemotherapy in breast cancer patients with ypN0 status does not compromise recurrence or survival outcomes.

Inconsistent Bone Health Management in Older Women With Breast Cancer: Insights From the Age Gap Study
Clinical Updatesaromatase inhibitorsbone health

Inconsistent Bone Health Management in Older Women With Breast Cancer: Insights From the Age Gap Study

By MedXY|Sep 30, 2025

Significant variation exists in bone health management for older women receiving endocrine therapy for breast cancer, highlighting the need for standardized care.

Antibody-Drug Conjugates in Breast Cancer: Efficacy, Toxicity, and Evolving Management Strategies
Clinical Updatesantibody-drug conjugatesbreast cancer

Antibody-Drug Conjugates in Breast Cancer: Efficacy, Toxicity, and Evolving Management Strategies

By MedXY|Sep 30, 2025

Antibody-drug conjugates (ADCs) have transformed breast cancer therapy but bring notable toxicity risks. This review examines the clinical evidence, adverse event management, and future directions for optimizing ADC use.

Removing Out-of-Pocket Costs Increases Access to 3D Mammograms
newsbreast cancerbreast cancer screening

Removing Out-of-Pocket Costs Increases Access to 3D Mammograms

By MedXY|Sep 30, 2025

Eliminating a $45 fee for advanced breast cancer screening technology improves access and reduces health disparities, according to recent research.

Understanding Hormone Therapy and Breast Cancer Risk in Younger Women
newsbreast cancerhormone therapy

Understanding Hormone Therapy and Breast Cancer Risk in Younger Women

By MedXY|Sep 30, 2025

Recent research highlights that estrogen-only hormone therapy may reduce breast cancer risk in women under 55, while combined estrogen-progestin therapy could increase risk.

Prev
4 / 4
1234
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities